bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
092-10-0023

Order Name:
Pharmacogenomics of cardiovascular drugs (CYP2C19, CYP2C9, VKORC1, SLCO1B1 - Fast track)

 
Useful For:
Identifying patients who may be at risk for altered metabolism of drugs that are modified by CYP2C19, CYP2C9, VKORC1 and SLCO1B1. Predicting anticoagulation response to antiplatelet (Clopidogrel/Plavix), proton pump inhibitors, antidepressants, antimalarial drugs, anticonvulsants, b-adrenergic blockers and antifungal (voriconazole), NSAID, Phenytoin and Warfarin, Simvastatin and Statin group.
 
Methodology:
Real-time PCR
 
AliasesName:
CYP2C19
CYP2C9
VKORC1
SLCO1B1
pgx
Pharmacogenetics
Pharmacogenomics
 
 
 
Test Code:
092-10-0023

Order Name:
Pharmacogenomics of cardiovascular drugs (CYP2C19, CYP2C9, VKORC1, SLCO1B1 - Fast track)

 
Collection Specimen Or Container:
Blood/ K3 EDTA (K3E) (Lavender Top) 3 mL, 2 tubes
 
Specimen Testing Type:
Whole blood, K3 EDTA (K3E) (Lavender Top) 3 mL, 2 tubes, minimum volume 1.5 ml
 
Sub Mission Container:
Original tube
 
Rejection Criteria:
Use heparin as anticoagulant, Severe clotted specimen will be reject.
 
Specimen Stabillity:
Specimen Type Temperature Time
EDTA Whole Blood Refrigerated, 2oC to 8oC 7 days
 
 
 
Test Code:
092-10-0023

Order Name:
Pharmacogenomics of cardiovascular drugs (CYP2C19, CYP2C9, VKORC1, SLCO1B1 - Fast track)

 
Method detail:
Real-time PCR
 
Schedule:
Test Daily
 
Turnaround Time:
Received specimen to report within 3 days
 
Performing Location:
Research and Development, Tel. 14252
 
Specimen Retention Time:
3 months
 
 
 
Test Code:
092-10-0023

Order Name:
Pharmacogenomics of cardiovascular drugs (CYP2C19, CYP2C9, VKORC1, SLCO1B1 - Fast track)

 
 
Clinical Information:
CYP2C19 is an important drug metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants, clopidogrel, voriconazole, and proton pump inhibitors.  This test identifies four common alleles (*1, *2, *3, *17) by Real-time PCR. This CYP2C19 detection test covers two known no functional alleles and one known rapid functional allele. 

CYP2C9 is an important drug metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including phenytoin, angiotensin II blockers, non-steroidal anti-inflammatory drugs, the alkylating anticancer prodrugs. This test identifies three common alleles (*1, *2, *3) by Real-time PCR. The CYP2C9 genotyping (2 SNP; Fast track) test covers two known no functional alleles. 

CYP2C9 and VKORC1 are an important drug metabolizing enzyme that catalyzes the biotransformation of warfarin. Inherited differences in VKORC1 increase or decrease the amount of warfarin needed to inhibit the formation of the clotting factors. When the amount of warfarin exceeds what is needed, the risk of bleeding is increased. This test identifies three common alleles in CYP2C9 (*1, *2, *3) and one common allele in VKORC1 by Real-time PCR. 

SLCO1B1 is an influx transporter that moves drugs into cells. Variations in SLCO1B1 may affect the blood levels of drugs that are substrates for this transporter. Statins are one of the most common classes of medications affected by this transporter. Variations that result in decreased transporter activity may result in increased statin blood levels and increase the risk of adverse effects, such as myalgia and rhabdomyolysis. SLCO1B1-based dosing guidelines are available for statins. Providers should consider genotyping patients who are initiating statin therapy or those who have experienced adverse effects to statins in the past. Genetic variants tested for SLCO1B1 are *1a, *1b,*5, *15,*17.
 
Clinical Reference:
  1. Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
  2. Pratt VM, et al. Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. J Mol Diagn. 2018 May;20(3):269-276. doi: 10.1016/j.jmoldx.2018.01.011. Epub 2018 Feb 21.
  3. Lima JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2020 Aug 8. doi: 10.1002/cpt.2015.
  4. Pratt VM, et al. Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.J Mol Diagn. 2019 Sep;21(5):746-755. doi: 10.1016/j.jmoldx.2019.04.003. Epub 2019 May 8."
  5. Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4.
  6. Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1 and Simvastatin-induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014 Oct;96(4):423-8. doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.